Source comparison
Sermorelin vs Exogenous Growth Hormone for Sleep
Mechanism Stimulates endogenous pulsatile GH release from pituitary Direct replacement. Suppresses endogenous production Variable (melatonin affects timing, GABA affects receptor activity) Sermorelin preserves natural pulsatility. Exogenous GH creates steady-s
This comparison does not assign a generated winner or score.
- Mechanism
- Stimulates endogenous pulsatile GH release from pituitary
- Direct replacement. Suppresses endogenous production
- Variable (melatonin affects timing, GABA affects receptor activity)
- Sermorelin preserves natural pulsatility. Exogenous GH creates steady-state levels that eventually suppress native secretion
- Slow-Wave Sleep Impact
- +30–45% duration in controlled trials using polysomnography
- +18–25%. Less than sermorelin despite higher GH levels
- Melatonin: minimal architecture change; GABA agonists: suppress Stage 3 in favor of Stage 2
- Pulsatile GH (sermorelin) synchronizes better with sleep cycles than steady-state GH
- Receptor Downregulation Risk
- Minimal. Preserves negative feedback loop
- High. Chronic exogenous GH suppresses GHRH receptors and somatotroph responsiveness
- Depends on compound (benzodiazepine tolerance well-documented)
- Sermorelin's brief half-life prevents receptor desensitization
- Cost (Monthly Protocol)
- $180–$320 for research-grade material
- $800–$1,400 for pharmaceutical rhGH
- $15–$60 for supplements
- Sermorelin sits between ineffective supplements and cost-prohibitive rhGH
- Regulatory Status
- Prescription required. Available through compounding pharmacies and research suppliers
- Schedule III controlled substance. Requires endocrinologist prescription
- OTC widely available
- Sermorelin's regulatory accessibility makes clinical trials and personal protocols more feasible